Drugs / MPB-1523
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03407495 | Nov 2018 → Aug 2020 | — | MegaPro Biomedical Co. Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MPB-1523 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03407495 ↗ |
| Known as | IOP Injection | “IOP Injection (MPB-1523)” NCT03407495 ↗ |
| Modality | Diagnostic / imaging agent | “MRI Contrast Agent” NCT03407495 ↗ |
| Route | Intravenous | “one dose, once IV injection at Day 1” NCT03407495 ↗ |